Eduardo Andreazza Dal Lago, MD
- Assistant Professor
Biography
LICENSURE:
Texas Medical Board – Physician in Training (ID number: 799192), 2025
Texas Medical Board FTL #48961, 03/01/2027
CERTIFICATION:
Brazilian Board of Radiology, 2014
Education
- Fellowship, Body MRI
- UTHealth Houston, 07/2025-02/2026
- Fellowship, Abdominal Radiology
- State University of Campinas, 03/2014-02/2015
- Residency
- Mackenzie Evangelical University Hospital, 02/2011-01/2014
- Internship
- Medical School of Pontifical Catholic University of Paraná, 2011
- Medical School
- Medical School of Pontifical Catholic University of Paraná, 2011
Publications
Publications
- Sousa LG, Lazar Neto F, Dal Lago EA, Sikora A, Hanna E, Moreno A, et al. Human papillomavirus status and prognosis of oropharyngeal high-grade neuroendocrine carcinoma. Oral Oncol. 2023;138:106311. doi:10.1016/j.oraloncology.2023.106311
- Ferrarotto R, Sousa LG, Feng L, Mott F, Blumenschein G, Altan M, et al. A phase 2 clinical trial of axitinib and avelumab in patients with recurrent/metastatic adenoid cystic carcinoma. J Clin Oncol. 2023;41(15):1996-2016. doi:10.1200/JCO.22.02221
- Dal Lago EA, Sousa LG, Yang Z, Hoff CO, Bonini F, Sawyer M, et al. Prognostic value of tumor volume doubling time in lung-metastatic adenoid cystic carcinoma. Oral Oncol. 2024;144:106759. doi:10.1016/j.oraloncology.2024.106759
- Hoff CO, Dal Lago EA, Siqueira JM, Sousa LG, El-Naggar AK, Rodon Ahnert J, Ferrarotto R. First use of AXL targeting in metastatic, refractory, adenoid cystic carcinoma: A case report. JCO Precis Oncol. 2024;8:ePO2300633. doi:10.1200/PO.23.00633
- Hoff CO, Sousa LG, Bonini F, Dal Lago EA, Wang K, Siqueira JM, et al. Clinical outcomes with Notch inhibitors in Notch-activated recurrent/metastatic adenoid cystic carcinoma. Cancer Med. 2025;14(10):1996-2016. doi:10.1002/cam4.70663